Danish pharmaceutical giant Novo Nordisk announced Wednesday that it would cut 11 percent of its workforce, as the maker of Ozempic and Wegovy faces rising competition for its anti-obesity treatments. - Copycats - Novo Nordisk faces stiff competition from rival treatments made by US group Eli Lilly.
Don't miss out on breaking stories and in-depth articles.
